109 related articles for article (PubMed ID: 38704606)
1. Comprehensive characterization of stemness-related lncRNAs in triple-negative breast cancer identified a novel prognostic signature related to treatment outcomes, immune landscape analysis and therapeutic guidance: a silico analysis with in vivo experiments.
Zhang M; Zhang F; Wang J; Liang Q; Zhou W; Liu J
J Transl Med; 2024 May; 22(1):423. PubMed ID: 38704606
[TBL] [Abstract][Full Text] [Related]
2. Stemness related lncRNAs signature for the prognosis and tumor immune microenvironment of ccRCC patients.
Zhang M; Zhang J; Liang X; Zhang M
BMC Med Genomics; 2024 May; 17(1):150. PubMed ID: 38822402
[TBL] [Abstract][Full Text] [Related]
3. The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer.
Yan Z; Zhong Z; Shi C; Feng M; Feng X; Liu T
Cancer Biol Ther; 2024 Dec; 25(1):2355705. PubMed ID: 38778753
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
[TBL] [Abstract][Full Text] [Related]
5. Constructing a novel prognostic model for triple-negative breast cancer based on genes associated with vasculogenic mimicry.
Ren Y; Feng L; Tan Z; Zhou F; Liu S
Aging (Albany NY); 2024 May; 16(9):8086-8109. PubMed ID: 38728245
[TBL] [Abstract][Full Text] [Related]
6. An immunogenic cell death-related lncRNA signature correlates with prognosis and tumor immune microenvironment in bladder cancer.
Luo J; Luo F; Li Q; Liu Q; Wang J
Sci Rep; 2024 Jun; 14(1):13106. PubMed ID: 38849410
[TBL] [Abstract][Full Text] [Related]
7. MIF as a potential diagnostic and prognostic biomarker for triple-negative breast cancer that correlates with the polarization of M2 macrophages.
Chen M; Liu H; Hong B; Xiao Y; Qian Y
FASEB J; 2024 May; 38(10):e23696. PubMed ID: 38787620
[TBL] [Abstract][Full Text] [Related]
8. Systematic Analysis of Tumor Stem Cell-related Gene Characteristics to Predict the PD-L1 Immunotherapy and Prognosis of Gastric Cancer.
Wang C; Chen Y; Zhou R; Yang Y; Fang Y
Curr Med Chem; 2024; 31(17):2467-2482. PubMed ID: 37936456
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic vulnerabilities in triple negative breast cancer: Stem-like traits explored within molecular classification.
Huang P; Zhang X; Prabhu JS; Pandey V
Biomed Pharmacother; 2024 May; 174():116584. PubMed ID: 38613998
[TBL] [Abstract][Full Text] [Related]
10. Cervical cancer-specific long non-coding RNA landscape reveals the favorable prognosis predictive performance of an ion-channel-related signature model.
Wang B; Wang W; Zhou W; Zhao Y; Liu W
Cancer Med; 2024 Jun; 13(11):e7389. PubMed ID: 38864475
[TBL] [Abstract][Full Text] [Related]
11. A novel signature incorporating genes related to lipid metabolism and immune for prognostic and functional prediction of breast cancer.
Zhao X; Yan L; Yang Z; Zhang H; Kong L; Zhang N; He Y
Aging (Albany NY); 2024 May; 16(10):8611-8629. PubMed ID: 38771140
[TBL] [Abstract][Full Text] [Related]
12. A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancers.
Liu M; Xing LQ; Liu YJ
Medicine (Baltimore); 2017 Mar; 96(9):e6222. PubMed ID: 28248879
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Molecular Analyses of an M2-Like Tumor-Associated Macrophage for Predicting the Prognosis and Immunotherapy in Breast Cancer.
Chang K; Yue Q; Jin L; Fan P; Liu Y; Cao F; Zhang Y
J Immunother; 2024 Jul-Aug 01; 47(6):205-215. PubMed ID: 38686904
[TBL] [Abstract][Full Text] [Related]
14. Integration of single-cell sequencing and bulk RNA-seq to identify and develop a prognostic signature related to colorectal cancer stem cells.
Wu J; Li W; Su J; Zheng J; Liang Y; Lin J; Xu B; Liu Y
Sci Rep; 2024 May; 14(1):12270. PubMed ID: 38806611
[TBL] [Abstract][Full Text] [Related]
15. Lactylproteome analysis indicates histone H4K12 lactylation as a novel biomarker in triple-negative breast cancer.
Cui Z; Li Y; Lin Y; Zheng C; Luo L; Hu D; Chen Y; Xiao Z; Sun Y
Front Endocrinol (Lausanne); 2024; 15():1328679. PubMed ID: 38779451
[TBL] [Abstract][Full Text] [Related]
16. Sphingolipids in prostate cancer prognosis: integrating single-cell and bulk sequencing.
Zhou S; Sun L; Mao F; Chen J
Aging (Albany NY); 2024 May; 16(9):8031-8043. PubMed ID: 38713159
[TBL] [Abstract][Full Text] [Related]
17. Harnessing the synergistic potential of NK1R antagonists and selective COX-2 inhibitors for simultaneous targeting of TNBC cells and cancer stem cells.
Singh MT; Thaggikuppe Krishnamurthy P; Magham SV
J Drug Target; 2024 Dec; 32(3):258-269. PubMed ID: 38252517
[TBL] [Abstract][Full Text] [Related]
18. Identification of molecular subtypes based on chromatin regulator-related genes and experimental verification of the role of ASCL1 in conferring chemotherapy resistance to breast cancer.
Li Y; Yang X; Geng C; Liu Y; Tang T; Zhang L; Liu F; Zhang M; Hao J; Ma L
Front Immunol; 2024; 15():1390261. PubMed ID: 38726001
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Novel Five-Gene Prognostic Model for Laryngeal Cancer Associated with Mitophagy Using Integrated Bioinformatics Analysis and Experimental Verification.
Song D; Dong L; Wang M; Gao X
Crit Rev Immunol; 2024; 44(6):75-85. PubMed ID: 38848295
[TBL] [Abstract][Full Text] [Related]
20. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies.
Xiong N; Wu H; Yu Z
Front Oncol; 2024; 14():1405491. PubMed ID: 38863622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
